TabletsClinical Overview
Combipack of Mifepristone 200mg (1 Tablet) & Misoprostol 200mcg (4 Tablets) is a sequential antiprogestogenic and prostaglandin regimen approved under the Medical Termination of Pregnancy (MTP) Act for the medical termination of intrauterine pregnancy up to 63 days (9 weeks) of gestation. Mifepristone blocks uterine progesterone receptors, terminating fetal viability and sensitizing the myometrium, followed by Misoprostol which stimulates strong myometrial contractions and cervical dilation to expel gestational products.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Strictly administered under supervision of an RMP certified under the MTP Act: Day 1: Swallow one Mifepristone 200 mg tablet with water. 24 to 48 hours later (Day 2 or 3): Administer four Misoprostol 200 mcg tablets (800 mcg total) buccally (placed between cheek and gum for 30 minutes before swallowing remnants) or sublingually. Follow-up clinical and ultrasonographic evaluation is mandatory on Day 14 to verify complete expulsion.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Expected/Common: Uterine cramping, vaginal bleeding (heavier than menses with clots), nausea, vomiting, diarrhea, chills, low-grade fever, and dizziness. Rare/Severe: Severe hemorrhage requiring surgical curettage or blood transfusion, incomplete abortion, pelvic infection/sepsis (rare Clostridium sordellii toxic shock), and ectopic pregnancy rupture.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Contraindicated in confirmed or suspected ectopic pregnancy, undiagnosed adnexal mass, IUD in situ (must be removed prior), chronic adrenal failure, severe unmanaged asthma, hemorrhagic disorders, concurrent anticoagulant therapy, and porphyria. Surgical abortion facilities and emergency blood transfusion must be accessible.
Schedule H (Prescription Required - MTP Act Compliant)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Gynecological, Obstetric & Endocrinological Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice or reproductive healthcare guidance. Hormonal medications, uterotonics, corticosteroids, fertility therapies, and emergency contraceptives have profound systemic actions and must be administered strictly under the supervision of a registered gynecologist, obstetrician, or endocrinologist.
Misoprostol Tablets 200 mcg
Misoprostol Tablets IP 200 mcg is a synthetic prostaglandin E1 (PGE1) analogue on the WHO Model List of Essential Medicines. It binds to myometrial prostanoid EP receptors, producing strong rhythmic uterine contractions and enzymatic cervical softening/effacement; it also inhibits gastric acid secretion and protects mucosal lining. Indicated for prevention and treatment of postpartum hemorrhage (PPH), cervical ripening and labor induction, medical termination of pregnancy (in combination with mifepristone), and prevention of NSAID-induced peptic ulcers.
Mifepristone Tablets 200 mg
Mifepristone Tablets IP 200 mg is a synthetic steroid with potent antiprogestational and antiglucocorticoid activity on the WHO Model List of Essential Medicines. It competitively binds with high affinity to intracellular progesterone receptors, disrupting the decidua, detachment of the blastocyst, and cervical softening. Indicated for medical termination of developing intrauterine pregnancy (in combination with prostaglandin), cervical preparation prior to surgical abortion, and induction of labor in intrauterine fetal death.